Literature DB >> 28671413

Alzheimer Disease: Pharmacologic and Nonpharmacologic Therapies for Cognitive and Functional Symptoms.

Ted Epperly1, Megan A Dunay2, Jack L Boice2.   

Abstract

Alzheimer disease comprises a syndrome of progressive cognitive and functional decline. Treatments should target cognitive and functional symptoms. Cholinesterase inhibitors, memantine, and a combination of a cholinesterase inhibitor and memantine have produced statistically significant but clinically small delays in various domains of cognitive and functional decline in select patients with Alzheimer disease. Vitamin E has been shown to delay functional decline in patients with mild to moderate Alzheimer disease, especially when taken in combination with a cholinesterase inhibitor. Structured programs of physical exercise improve physical function and reduce rates of neuropsychiatric symptoms in patients with mild to severe Alzheimer disease. Cognitive stimulation programs show benefit in maintenance of cognitive function and improved self-reported quality of life in patients with mild to moderate Alzheimer disease.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28671413

Source DB:  PubMed          Journal:  Am Fam Physician        ISSN: 0002-838X            Impact factor:   3.292


  20 in total

Review 1.  Neurochemical mechanisms for memory processing during sleep: basic findings in humans and neuropsychiatric implications.

Authors:  Gordon B Feld; Jan Born
Journal:  Neuropsychopharmacology       Date:  2019-08-23       Impact factor: 7.853

2.  Yizhi Qingxin Formula Extract Ameliorates Cognitive Decline in Aged Rats via the Brain-Derived Neurotrophic Factor/Tropomyosin Receptor Kinase B Pathway.

Authors:  Lina Ma; Yu Cao; Feixue Wang; Zehui Li; Zhiyong Wang; Yang Yang; Hui Pei; Hao Li
Journal:  Front Pharmacol       Date:  2020-04-30       Impact factor: 5.810

Review 3.  Some Candidate Drugs for Pharmacotherapy of Alzheimer's Disease.

Authors:  Barbara Miziak; Barbara Błaszczyk; Stanisław J Czuczwar
Journal:  Pharmaceuticals (Basel)       Date:  2021-05-13

4.  Deep learning prediction of mild cognitive impairment conversion to Alzheimer's disease at 3 years after diagnosis using longitudinal and whole-brain 3D MRI.

Authors:  Ethan Ocasio; Tim Q Duong
Journal:  PeerJ Comput Sci       Date:  2021-05-25

5.  Repetitive Transcranial Magnetic Stimulation Improves Brain-Derived Neurotrophic Factor and Cholinergic Signaling in the 3xTgAD Mouse Model of Alzheimer's Disease.

Authors:  M Windy McNerney; Alesha Heath; Sindhu K Narayanan; Jerome Yesavage
Journal:  J Alzheimers Dis       Date:  2022       Impact factor: 4.160

Review 6.  Exercise Intervention Associated with Cognitive Improvement in Alzheimer's Disease.

Authors:  Meng Ying Cui; Yang Lin; Ji Yao Sheng; Xuewen Zhang; Ran Ji Cui
Journal:  Neural Plast       Date:  2018-03-11       Impact factor: 3.599

7.  Brain delivery of quercetin-loaded exosomes improved cognitive function in AD mice by inhibiting phosphorylated tau-mediated neurofibrillary tangles.

Authors:  Yao Qi; Lin Guo; Yibing Jiang; Yijie Shi; Haijuan Sui; Liang Zhao
Journal:  Drug Deliv       Date:  2020-12       Impact factor: 6.419

8.  Psychosocial interventions for Alzheimer's disease cognitive symptoms: a Bayesian network meta-analysis.

Authors:  Yuting Duan; Liming Lu; Juexuan Chen; Chunxiao Wu; Jielin Liang; Yan Zheng; Jinjian Wu; Peijing Rong; Chunzhi Tang
Journal:  BMC Geriatr       Date:  2018-08-07       Impact factor: 3.921

9.  Intention to Screen for Alzheimer's Disease by Residential Locale.

Authors:  Lilah M Besser; Willa D Brenowitz; Juyoung Park; Magdalena I Tolea; James E Galvin
Journal:  Int J Environ Res Public Health       Date:  2020-03-27       Impact factor: 3.390

10.  Acupuncture therapy for Alzheimer's disease: A protocol for an overview of systematic reviews.

Authors:  Liaoyao Wang; Jia Xu; Yijun Zhan; Jian Pei
Journal:  Medicine (Baltimore)       Date:  2020-05-22       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.